REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
9.36
-0.27 (-2.80%)
Nov 21, 2024, 12:57 PM EST - Market open

REGENXBIO Statistics

Total Valuation

REGENXBIO has a market cap or net worth of $463.74 million. The enterprise value is $344.36 million.

Market Cap 463.74M
Enterprise Value 344.36M

Important Dates

The last earnings date was Wednesday, November 6, 2024, after market close.

Earnings Date Nov 6, 2024
Ex-Dividend Date n/a

Share Statistics

REGENXBIO has 49.55 million shares outstanding. The number of shares has increased by 9.71% in one year.

Current Share Class 49.55M
Shares Outstanding 49.55M
Shares Change (YoY) +9.71%
Shares Change (QoQ) +0.39%
Owned by Insiders (%) 7.58%
Owned by Institutions (%) 80.73%
Float 40.60M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 5.46
Forward PS 1.97
PB Ratio 1.58
P/TBV Ratio 1.58
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 4.08
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.05, with a Debt / Equity ratio of 0.48.

Current Ratio 3.05
Quick Ratio 2.93
Debt / Equity 0.48
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -52.13

Financial Efficiency

Return on equity (ROE) is -71.87% and return on invested capital (ROIC) is -29.81%.

Return on Equity (ROE) -71.87%
Return on Assets (ROA) -26.03%
Return on Capital (ROIC) -29.81%
Revenue Per Employee $245,137
Profits Per Employee -$694,201
Employee Count 344
Asset Turnover 0.15
Inventory Turnover n/a

Taxes

Income Tax -152,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -53.67% in the last 52 weeks. The beta is 1.23, so REGENXBIO's price volatility has been higher than the market average.

Beta (5Y) 1.23
52-Week Price Change -53.67%
50-Day Moving Average 10.31
200-Day Moving Average 14.25
Relative Strength Index (RSI) 43.70
Average Volume (20 Days) 877,817

Short Selling Information

The latest short interest is 4.91 million, so 9.91% of the outstanding shares have been sold short.

Short Interest 4.91M
Short Previous Month 4.99M
Short % of Shares Out 9.91%
Short % of Float 12.09%
Short Ratio (days to cover) 9.78

Income Statement

In the last 12 months, REGENXBIO had revenue of $84.33 million and -$238.81 million in losses. Loss per share was -$5.00.

Revenue 84.33M
Gross Profit -164.98M
Operating Income -240.08M
Pretax Income -241.23M
Net Income -238.81M
EBITDA -223.55M
EBIT -240.08M
Loss Per Share -$5.00
Full Income Statement

Balance Sheet

The company has $255.46 million in cash and $145.81 million in debt, giving a net cash position of $132.76 million or $2.68 per share.

Cash & Cash Equivalents 255.46M
Total Debt 145.81M
Net Cash 132.76M
Net Cash Per Share $2.68
Equity (Book Value) 301.42M
Book Value Per Share 6.09
Working Capital 210.67M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$182.26 million and capital expenditures -$2.48 million, giving a free cash flow of -$184.74 million.

Operating Cash Flow -182.26M
Capital Expenditures -2.48M
Free Cash Flow -184.74M
FCF Per Share -$3.73
Full Cash Flow Statement

Margins

Gross margin is -195.65%, with operating and profit margins of -284.70% and -283.19%.

Gross Margin -195.65%
Operating Margin -284.70%
Pretax Margin -283.37%
Profit Margin -283.19%
EBITDA Margin -265.10%
EBIT Margin -284.70%
FCF Margin -218.67%

Dividends & Yields

REGENXBIO does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -9.71%
Shareholder Yield -9.71%
Earnings Yield -50.05%
FCF Yield -38.72%

Analyst Forecast

The average price target for REGENXBIO is $36.36, which is 288.46% higher than the current price. The consensus rating is "Strong Buy".

Price Target $36.36
Price Target Difference 288.46%
Analyst Consensus Strong Buy
Analyst Count 12
Revenue Growth Forecast (5Y) 45.69%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

REGENXBIO has an Altman Z-Score of -1.22 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -1.22
Piotroski F-Score 4